Follow Us on Google
The Board of Directors of Neimeth International Pharmaceuticals Plc. has approved the appointment of Gerald I. Oputa as its acting Managing Director/CEO.
His appointment followed the retirement of Mr Matthew Obi Azoji, the Managing Director/CE of Company effective June 5, 2023, having attained the retirement age and proceeding on pre-retirement leave from March 6, 2023.
Oputa joined the Company as Executive Director Sales and Marketing on April 16, 2022.
Gerald I. Oputa as the acting Managing Director/CEO. Pharm. Gerald 1. Oputa joined the Company as Executive Director Sales and Marketing on the 161 April 2022.
Gerald I. Oputa comes on board with a wealth of experience from pharmaceutical industry spanning Evans Medical Plc, Agbara, Ranbaxy Nigeria Limited, Nub Pharmaceuticals Limited (AstraZeneca), Quixopharm Nigeria Limited, DEXA-Medica, Emzor Pharmaceutical Ind. Limited, Dana Drugs Limited.
Oputa becomes the acting Managing Director/CEO from March 6, 2023 and is expected to bring his wealth of experience to lead a turnaround to achieve optimum marketing of Neimeth’s broad range of products and to attain a new level of value creation for all shareholders.
Speaking on the appointment Board Chairman Dr ABC Orjiako said “We trust you will extend the usual hand of support and cooperation to Gerald I. Oputa as he pilots the affairs of Neimeth International Pharmaceuticals Plc.
